{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:37:43Z","timestamp":1757623063653,"version":"3.44.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002380","name":"Hanyang University","doi-asserted-by":"publisher","award":["HY-202300000003524"],"award-info":[{"award-number":["HY-202300000003524"]}],"id":[{"id":"10.13039\/501100002380","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Bruton tyrosine kinase inhibitors (BTKis) are effective and well-tolerated treatments for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Here, we describe the clinical characteristics of hepatitis B virus (HBV) reactivation in patients with hematological malignancies treated with BTKis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients were required to have a pathologically confirmed diagnosis of CLL or MCL, receive at least one cycle of ibrutinib or zanubrutinib, and have either positive hepatitis B surface antigen or hepatitis B core antibody at diagnosis. Patients were excluded if they had received rituximab or obinutuzumab within the previous 12\u00a0months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We identified five patients with CLL and one with MCL who had resolved HBV infections and received BTKis during the study period. None of the patients received anti-HBV prophylaxis after CLL diagnosis. The patient with MCL who received zanubrutinib was confirmed to have HBV reactivation even after prophylactic entecavir administration followed by tenofovir. All five patients with CLL received ibrutinib as second-line therapy. A 62-year-old man died of hepatorenal syndrome associated with HBV reactivation despite entecavir treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>To the best of our knowledge, this is the first description of HBV-related death in patients receiving BTKis from HBV-endemic areas, and the first case of HBV reactivation associated with zanubrutinib despite previous entecavir prophylaxis. Further prospective studies are warranted to develop useful guidelines for monitoring HBV DNA and antiviral prophylaxis to prevent HBV reactivation after BTKi therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s44313-025-00093-3","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T07:14:50Z","timestamp":1755242090000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors"],"prefix":"10.1007","volume":"60","author":[{"given":"Joon Young","family":"Hur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Je-Hwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Seung","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunkyung","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunsuk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Hye","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Woong","family":"Won","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Eun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"93_CR1","doi-asserted-by":"crossref","unstructured":"Kim LY, Yoo JJ, Chang Y, Korean Association for the Study of the Liver, et al. The epidemiology of hepatitis B virus infection in Korea: 15-year analysis. J Korean Med Sci. 2024;39:e22.","DOI":"10.3346\/jkms.2024.39.e22"},{"key":"93_CR2","doi-asserted-by":"crossref","unstructured":"Burger JA, Tedeschi A, Barr PM, RESONATE-2 Investigators, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425\u201337.","DOI":"10.1056\/NEJMoa1509388"},{"key":"93_CR3","doi-asserted-by":"crossref","unstructured":"Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507\u201316.","DOI":"10.1056\/NEJMoa1306220"},{"key":"93_CR4","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","volume":"378","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Tedeschi A, Trotman J. Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med. 2018;378:2399\u2013410.","journal-title":"N Engl J Med"},{"key":"93_CR5","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, Doorduijn J, Gin\u00e9 E, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024;403:2293\u2013306.","journal-title":"Lancet"},{"key":"93_CR6","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","volume":"130","author":"D Miklos","year":"2017","unstructured":"Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130:2243\u201350.","journal-title":"Blood"},{"key":"93_CR7","doi-asserted-by":"publisher","first-page":"4782","DOI":"10.1038\/srep04782","volume":"4","author":"A Turetsky","year":"2014","unstructured":"Turetsky A, Kim E, Kohler RH, et al. Single cell imaging of Bruton\u2019s tyrosine kinase using an irreversible inhibitor. Sci Rep. 2014;4:4782.","journal-title":"Sci Rep"},{"key":"93_CR8","first-page":"208","volume":"37","author":"G \u0130skender","year":"2020","unstructured":"\u0130skender G, \u0130skender D, Ertek M. Hepatitis B virus reactivation under ibrutinib treatment in a patient with chronic lymphocytic leukemia. Turk J Haematol. 2020;37:208\u20139.","journal-title":"Turk J Haematol"},{"key":"93_CR9","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.3324\/haematol.2021.280325","volume":"107","author":"I Innocenti","year":"2022","unstructured":"Innocenti I, Reda G, Visentin A, et al. Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study. Haematologica. 2022;107:1470\u20133.","journal-title":"Haematologica"},{"key":"93_CR10","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1182\/blood-2018-01-826495","volume":"131","author":"SP Hammond","year":"2018","unstructured":"Hammond SP, Chen K, Pandit A, et al. Risk of hepatitis B virus reactivation in patients treated with ibrutinib. Blood. 2018;131:1987\u20139.","journal-title":"Blood"},{"key":"93_CR11","doi-asserted-by":"publisher","first-page":"704","DOI":"10.4143\/crt.2022.1524","volume":"55","author":"JH Choi","year":"2023","unstructured":"Choi JH, Hur JY, Won YW. Hepatitis B virus reactivation in a chronic lymphocytic leukemia patient treated with ibrutinib. Cancer Res Treat. 2023;55:704\u20135.","journal-title":"Cancer Res Treat"},{"key":"93_CR12","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.clml.2023.04.006","volume":"23","author":"CY Chiu","year":"2023","unstructured":"Chiu CY, Ahmed S, Thomas SK, et al. Hepatitis B virus reactivation in patients receiving Bruton tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk. 2023;23:610\u20135.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"93_CR13","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1200\/JCO.20.01757","volume":"38","author":"JP Hwang","year":"2020","unstructured":"Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020;38:3698\u2013715.","journal-title":"J Clin Oncol"},{"key":"93_CR14","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u201399.","journal-title":"Hepatology"},{"key":"93_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000518398","volume":"145","author":"S Yang","year":"2022","unstructured":"Yang S, Zhu R, Li N, et al. Ibrutinib in advanced chronic lymphocytic leukemia\/small lymphocytic lymphoma: lower risk of hepatitis B virus reactivation. Acta Haematol. 2022;145:54\u201362.","journal-title":"Acta Haematol"},{"key":"93_CR16","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1080\/10428194.2018.1436175","volume":"59","author":"S Molica","year":"2018","unstructured":"Molica S, Levato L, Mirabelli R, et al. Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients. Leuk Lymphoma. 2018;59:2734\u20136.","journal-title":"Leuk Lymphoma"},{"key":"93_CR17","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","volume":"6","author":"PM Barr","year":"2022","unstructured":"Barr PM, Owen C, Robak T, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6:3440\u201350.","journal-title":"Blood Adv"},{"key":"93_CR18","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1007\/s40121-023-00860-8","volume":"12","author":"Y Cho","year":"2023","unstructured":"Cho Y, Park S, Park S, Choi W, Kim B, Han H. Real-world epidemiology, treatment patterns, and disease burden of chronic hepatitis B and HDV co-infection in South Korea. Infect Dis Ther. 2023;12:2387\u2013403.","journal-title":"Infect Dis Ther"},{"key":"93_CR19","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1038\/s41375-019-0481-1","volume":"33","author":"KA Rogers","year":"2019","unstructured":"Rogers KA, Mousa L, Zhao Q, et al. Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. Leukemia. 2019;33:2527\u201330.","journal-title":"Leukemia"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00093-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-025-00093-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00093-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T02:46:21Z","timestamp":1757385981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-025-00093-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["93"],"URL":"https:\/\/doi.org\/10.1007\/s44313-025-00093-3","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"type":"print","value":"2287-979X"},{"type":"electronic","value":"2288-0011"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board (IRB) of Hanyang University Guri Hospital (2024\u201310-035). The requirement for informed consent was waived because of the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}